HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue43792133
Cost of Revenue1,1831,1081,598
Gross Profit-746-1,016-1,465
Operating Expenses
Research Development4,0985,1078,038
Selling General and Administrative6,5727,6817,147
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-11,416-13,804-16,650
Income from Continuing Operations
Total Other Income/Expenses Net3,2966,3021,423
Earnings Before Interest and Taxes-8,120-7,502-15,227
Interest Expense1391393
Income Before Tax-8,259-7,502-15,230
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-8,259-7,502-15,230
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-8,259-7,502-15,230
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-8,259-7,502-15,230